Advertisement Pharmaceutical Business review - Page 582 of 5272 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 8, 2026

Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn

Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its focus on brain health and rare diseases.

Upon acquisition, Angelini Pharma will integrate Catalyst’s portfolio and infrastructure to advance rare disease therapies. Credit: MrWinn / Shutterstock.com.